Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
Donnelly L, Curran RM, Tregoning JS, McKay PF, Cole T, Morrow RJ, Kett VL, Andrews GP, Woolfson AD, Malcolm RK, Shattock RJ. Donnelly L, et al. Among authors: shattock rj. Vaccine. 2011 Jun 15;29(27):4512-20. doi: 10.1016/j.vaccine.2011.04.023. Epub 2011 Apr 21. Vaccine. 2011. PMID: 21514349 Free PMC article.
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.
Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, Cranage M, Malcolm RK, Shattock RJ, Woolfson AD. Curran RM, et al. Among authors: shattock rj. Vaccine. 2009 Nov 12;27(48):6791-8. doi: 10.1016/j.vaccine.2009.08.088. Epub 2009 Sep 10. Vaccine. 2009. PMID: 19747994 Free PMC article.
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Cranage MP, et al. Among authors: shattock rj. Vaccine. 2011 Feb 4;29(7):1421-30. doi: 10.1016/j.vaccine.2010.12.034. Epub 2010 Dec 25. Vaccine. 2011. PMID: 21187177 Free PMC article.
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BC, Woolfson AD, Moore JP, Malcolm RK. Forbes CJ, et al. Among authors: shattock rj. J Control Release. 2011 Dec 10;156(2):161-9. doi: 10.1016/j.jconrel.2011.08.006. Epub 2011 Aug 12. J Control Release. 2011. PMID: 21864598 Free PMC article.
Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.
Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope A, Cai C, Giemza R, Jeffs SA, Manoussaka M, Cole T, Cranage MP, Shattock RJ, Lacey CJ. Lewis DJ, et al. Among authors: shattock rj. PLoS One. 2011;6(9):e25165. doi: 10.1371/journal.pone.0025165. Epub 2011 Sep 30. PLoS One. 2011. PMID: 21984924 Free PMC article. Clinical Trial.
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP. Malcolm RK, et al. Among authors: shattock rj. Antimicrob Agents Chemother. 2012 May;56(5):2251-8. doi: 10.1128/AAC.05810-11. Epub 2012 Feb 13. Antimicrob Agents Chemother. 2012. PMID: 22330914 Free PMC article.
268 results